Do analysts prefer ZSQR or PLX?

Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 415.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer ZSQR or PLX?

In the previous week, Coeptis Therapeutics had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Coeptis Therapeutics and 1 mentions for Protalix BioTherapeutics. Coeptis Therapeutics' average media sentiment score of 0.17 beat Protalix BioTherapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PLX or ACRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Protalix BioTherapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Protalix BioTherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OCS or PLX?

In the previous week, Oculis had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Oculis and 1 mentions for Protalix BioTherapeutics. Oculis' average media sentiment score of 0.22 beat Protalix BioTherapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRMD or PLX?

In the previous week, CorMedix had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Protalix BioTherapeutics. CorMedix's average media sentiment score of 0.51 beat Protalix BioTherapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CADL or PLX?

In the previous week, Candel Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Candel Therapeutics and 1 mentions for Protalix BioTherapeutics. Candel Therapeutics' average media sentiment score of 0.38 beat Protalix BioTherapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Protalix BioTherapeutics (PLX) Competitors

$2.33 -0.02 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.36 +0.03 (+1.24%)

As of 07:50 PM Eastern

Compare

PLX vs. ZSQR, ACRS, OCS, CRMD, and CADL

Should you buy Protalix BioTherapeutics stock or one of its competitors? MarketBeat compares Protalix BioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protalix BioTherapeutics include Coeptis Therapeutics (ZSQR), Aclaris Therapeutics (ACRS), Oculis (OCS), CorMedix (CRMD), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Protalix BioTherapeutics compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Protalix BioTherapeutics has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	400.10	-$11.92M	-$2.52	N/A
Protalix BioTherapeutics	$76.38M	2.46	$8.31M	$0.18	12.94

In the previous week, Coeptis Therapeutics had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Coeptis Therapeutics and 1 mentions for Protalix BioTherapeutics. Coeptis Therapeutics' average media sentiment score of 0.17 beat Protalix BioTherapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has a net margin of -21.03% compared to Coeptis Therapeutics' net margin of -810.04%. Protalix BioTherapeutics' return on equity of -30.89% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 415.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Coeptis Therapeutics has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Protalix BioTherapeutics has a net margin of -21.03% compared to Aclaris Therapeutics' net margin of -832.58%. Protalix BioTherapeutics' return on equity of -30.89% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.46	$8.31M	$0.18	12.94
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Protalix BioTherapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Protalix BioTherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 415.02%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 117.39%. Given Protalix BioTherapeutics' higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Protalix BioTherapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Oculis?

Oculis (NASDAQ:OCS) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 176.38%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 415.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Protalix BioTherapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$2.13	N/A
Protalix BioTherapeutics	$76.38M	2.46	$8.31M	$0.18	12.94

In the previous week, Oculis had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Oculis and 1 mentions for Protalix BioTherapeutics. Oculis' average media sentiment score of 0.22 beat Protalix BioTherapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Protalix BioTherapeutics has a net margin of -21.03% compared to Oculis' net margin of -8,460.67%. Protalix BioTherapeutics' return on equity of -30.89% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

22.3% of Oculis shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Protalix BioTherapeutics beats Oculis on 9 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

CorMedix has a net margin of 45.25% compared to Protalix BioTherapeutics' net margin of -21.03%. CorMedix's return on equity of 45.57% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 91.08%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 415.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

CorMedix has higher revenue and earnings than Protalix BioTherapeutics. CorMedix is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69
Protalix BioTherapeutics	$76.38M	2.46	$8.31M	$0.18	12.94

In the previous week, CorMedix had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Protalix BioTherapeutics. CorMedix's average media sentiment score of 0.51 beat Protalix BioTherapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CorMedix beats Protalix BioTherapeutics on 12 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Candel Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Candel Therapeutics and 1 mentions for Protalix BioTherapeutics. Candel Therapeutics' average media sentiment score of 0.38 beat Protalix BioTherapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 74.76%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 415.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Candel Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Protalix BioTherapeutics	$76.38M	2.46	$8.31M	$0.18	12.94

Summary

Protalix BioTherapeutics beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$187.73M	$351.52M	$6.87B	$23.41B
Dividend Yield	N/A	N/A	2.67%	4.07%
P/E Ratio	-17.92	N/A	27.51	31.92
Price / Sales	2.46	186.49	540.69	21.80
Price / Cash	17.80	22.44	48.53	25.04
Price / Book	4.96	4.86	11.01	4.80
Net Income	$8.31M	-$141.03M	$3.57B	$1.07B
7 Day Performance	7.37%	0.77%	2.56%	1.42%
1 Month Performance	10.43%	-2.16%	0.89%	0.71%
1 Year Performance	57.43%	78.79%	36.84%	25.93%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.5792 of 5 stars	$2.33 -0.9%	$12.00 +415.0%	+52.6%	$187.73M	$76.38M	N/A	200
ZSQR Coeptis Therapeutics	0.167 of 5 stars	$13.38 -9.0%	N/A	+50.0%	$688.13M	$1.36M	N/A	2	News Coverage Short Interest Increase High Trading Volume
ACRS Aclaris Therapeutics	3.1562 of 5 stars	$4.92 +1.7%	$11.50 +133.7%	+241.5%	$687.15M	$8.37M	N/A	100
OCS Oculis	3.2858 of 5 stars	$11.72 +0.4%	$38.33 +227.1%	-32.4%	$679.53M	$1.45M	N/A	2	Short Interest Increase Gap Down
CRMD CorMedix	3.1588 of 5 stars	$8.60 -2.5%	$15.00 +74.4%	-38.9%	$674.67M	$311.71M	4.04	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ZSQR, ACRS, OCS, CRMD, and CADL

How does Protalix BioTherapeutics compare to Coeptis Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Oculis?

Summary

How does Protalix BioTherapeutics compare to CorMedix?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ZSQR, ACRS, OCS, CRMD, and CADL

How does Protalix BioTherapeutics compare to Coeptis Therapeutics?

Which has preferable valuation and earnings, ZSQR or PLX?

Does the media prefer ZSQR or PLX?

Do insiders & institutionals hold more shares of ZSQR or PLX?

Is ZSQR or PLX more profitable?

Do analysts prefer ZSQR or PLX?

Which has more volatility and risk, ZSQR or PLX?

Summary

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Is PLX or ACRS more profitable?

Do insiders and institutionals hold more shares of PLX or ACRS?

Which has preferable earnings & valuation, PLX or ACRS?

Does the media favor PLX or ACRS?

Do analysts prefer PLX or ACRS?

Which has more volatility & risk, PLX or ACRS?

Summary

How does Protalix BioTherapeutics compare to Oculis?

Do analysts prefer OCS or PLX?

Which has higher earnings & valuation, OCS or PLX?

Does the media prefer OCS or PLX?

Which has more risk and volatility, OCS or PLX?

Is OCS or PLX more profitable?

Do institutionals & insiders have more ownership in OCS or PLX?

Summary

How does Protalix BioTherapeutics compare to CorMedix?

Is CRMD or PLX more profitable?

Do analysts prefer CRMD or PLX?

Which has higher earnings & valuation, CRMD or PLX?

Does the media refer more to CRMD or PLX?

Which has more risk & volatility, CRMD or PLX?

Do institutionals and insiders believe in CRMD or PLX?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Does the media refer more to CADL or PLX?

Do analysts recommend CADL or PLX?

Do institutionals and insiders have more ownership in CADL or PLX?

Which has more risk and volatility, CADL or PLX?

Is CADL or PLX more profitable?

Which has stronger valuation and earnings, CADL or PLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools